Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for B-cell…
Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses, and the treatment landscape is entrenched with targeted agents. Roche’s Rituxan, Janssen / AbbVie’s…
The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year…
Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…
MARKET OUTLOOK Relapsed/refractory diffuse large B-cell lymphoma (R/RDLBCL) represents an area of high unmet need in non-Hodgkin’s lymphoma (NHL) due to the poor outcomes with current salvage…
MARKET OUTLOOKRelapsed/refractory diffuse large B-cell lymphoma (R/RDLBCL) represents an area of high unmet need in non-Hodgkin’s lymphoma (NHL) due to the poor outcomes with current salvage…
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of NHL treatment, and recent…
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of NHL treatment, and recent…
Introduction: Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL …
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma ( NHL ) therapy market over the…